Novartis Pharmaceuticals Australia Pty Ltd v Bayer Australia Ltd

Link copied
Case Copied 85 min read

FEDERAL COURT OF AUSTRALIA

Novartis Pharmaceuticals Australia Pty Ltd v Bayer Australia Ltd [2015] FCA 35

Citation: Novartis Pharmaceuticals Australia Pty Ltd v Bayer Australia Ltd [2015] FCA 35
Parties: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD (ACN 004 244 160) v BAYER AUSTRALIA LIMITED (ACN 000 138 714)
File number: NSD 314 of 2013
Judge: ROBERTSON J
Date of judgment: 6 February 2015
Catchwords: TRADE PRACTICES – respondent’s conduct promoting new drug for the treatment, by intra-vitreal injection, of neovascular (wet) age-related macular degeneration  (AMD) – incumbent drug and new drug in direct competition with each other as prescription-only medicines indicated for use in Australia for the treatment of wet AMD – each drug only available on prescription and administered only by ophthalmologists – each drug registered on the Australian Register of Therapeutic Goods and listed on the Schedule of Pharmaceutical Benefits – illegal to advertise prescription-only medicines to the general public – relevant class of addressees – whether pleaded representations conveyed – if so, whether that conduct misleading or deceptive or likely to mislead or deceive or false or misleading – relevance of “dominant message” – whether applicant’s loss of sales caused by respondent’s representations – assessment of any loss
Legislation:

Australian Consumer Law ss 18, 29, 236 and 237
National Health Act 1953 (Cth) s 85
Therapeutic Goods Act 1989 (Cth) ss 3, 7D, 23 and 25

Therapeutic Goods Regulations 1990 (Cth) r 9A and sch 12

Cases cited: Apotex Pty Ltd (formerly GenRx Pty Ltd) v Les Laboratoires Servier (No 2) [2008] FCA 607; (2008) 77 IPR 1
AstraZeneca Pty Ltd v GlaxoSmithKline Australia Pty Ltd [2005] FCA 1645
Astrazeneca Pty Ltd v GlaxoSmithKline Australia Pty Ltd [2006] FCAFC 22; [2006] ATPR 42-106
Australian Competition and Consumer Commission v Dukemaster Pty Ltd [2009] FCA 682
Australian Competition and Consumer Commission v Jewellery Group Pty Ltd [2012] FCA 848; (2012) 293 ALR 335
Australian Competition and Consumer Commission v Pest Free Australia Pty Ltd [2004] FCA 527
Australian Competition and Consumer Commission v Telstra Corporation Ltd [2004] FCA 987; (2004) 208 ALR 459
Australian Competition and Consumer Commission v Telstra Corporation Ltd [2007] FCA 1904; (2007) 244 ALR 470
Australian Competition and Consumer Commission v TPG Internet Pty Ltd [2013] HCA 54; (2013) 250 CLR 640
Campomar Sociedad, Limitada v Nike International Ltd [2000] HCA 12; (2000) 202 CLR 45
Global One Mobile Entertainment Pty Ltd v Australian Competition and Consumer Commission [2012] FCAFC 134
Gould v Vaggelas (1984) 157 CLR 215
Instant Colour Pty Ltd v Canon Australia Pty Ltd [1996] FCA 763
National Exchange Pty Ltd v Australian Securities and Investments Commission [2004] FCAFC 90; (2004) 49 ACSR 369; (2004) 61 IPR 420
Newbon v City Mutual Life Assurance Society Ltd (1935) 52 CLR 723
Nick Scali Ltd v Super A-Mart Pty Ltd [2011] FCA 751
Parkdale Custom Built Furniture Pty Ltd v Puxu Pty Ltd (1982) 149 CLR 191
Sidhu v Van Dyke [2014] HCA 19;
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis Pharmaceuticals Australia Pty Ltd v Bayer Australia... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 35
Decision Date

CaseChat Overview and Summary

Novartis Pharmaceuticals Australia Pty Ltd (the applicant) brought proceedings against Bayer Australia Ltd (the respondent) regarding the latter's conduct in promoting its new drug, Eylea, which is used for the treatment of neovascular (wet) age-related macular degeneration (AMD). Both Eylea and the applicant's drug, Lucentis, were prescription-only medicines that were in direct competition with each other and were listed on the Schedule of Pharmaceutical Benefits. The applicant alleged that the respondent's conduct, which included a promotional campaign, was misleading or deceptive, or likely to mislead or deceive, in contravention of section 18 of the Australian Consumer Law. The matter was heard by the Federal Court.

The court was required to determine whether the respondent's conduct conveyed the pleaded representations, whether those representations were misleading or deceptive or likely to mislead or deceive, and whether the applicant's loss of sales was caused by the respondent's representations. The court also had to assess the extent of any loss, and the relevance of the dominant message conveyed by the respondent's promotional campaign.

The court found that the respondent's conduct conveyed the pleaded representations and was misleading or deceptive. The court rejected the argument that the dominant message of the promotional campaign was not misleading, as the court found that the representations made by the respondent were likely to mislead or deceive. The court held that the applicant's loss of sales was caused by the respondent's representations, and damages should be calculated as per Mr Moore’s scenario 2 using the historical loss figure but with future loss limited to the end of December 2013. The court did not include a sum for pre-judgment interest. The court ordered the parties to identify which parts of the reasons should not be published due to confidentiality, and to agree on the figure to be included in a particular paragraph of the reasons. The matter was stood over for four weeks to allow the parties to do this and to file submissions regarding costs. The proceedings were listed for the making of final orders.

Orders

Orders of the court

1. On or before 20 February 2015, the parties are to identify which parts of the reasons they contend should not be published because of confidentiality and file a proposed form of orders.

2. The parties are to endeavour to agree the figure to be included in [366] of these reasons.

3. If the applicant wishes to contend that costs should not follow the event, it should file and serve by 20 February 2015 a written submission of no more than three pages in support of that contention. If the applicant files such a written submission, the respondent is to file and serve by 28 February 2015 its written submission of no more than three pages in response.

4. The proceedings be listed at 9.30 am on 6 March 2015 for the making of orders.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Damages should therefore be calculated as per Mr Moore’s scenario 2 using the historical loss figure but with future loss limited to the end of December 2013. That figure is XXXXX XXX plus a tax gross up of XXXXX XX; it does not include a sum for pre-judgment interest.Conclusion Having made my reasons available to the parties I will stand the matter over for four weeks to enable them to identify which parts of the reasons should not be published because of confidentiality and to arrive at a proposed form of orders. The parties should also agree the figure to be included, even if not published, in the immediately preceding paragraph of these reasons. At that time I will make final orders dismissing the application. If the applicant contends that costs should not follow the event, it should file and serve within 14 days of the date of these reasons a written submission of no more than three pages in support of that contention. The respondent should file and serve within 21 days of the date of these reasons its written submission of no more than three pages in answer to any such submission of the applicant.

Ratio Decidendi

Legal Principle Established